Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic
effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view …

Recent years have witnessed increasingly rapid advances in nanocarrier-based
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …

Both T-cell deprivation and insufficient tumor immunogenicity seriously hinder the efficacy of
immune-mediated tumor destruction in melanoma. In this work, an amphiphilic polyethylene …

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses
in patients with many different types of cancer; however, most patients who receive ICB …

Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of
disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial …

Cancer vaccines aim at eliciting tumor‐specific responses for the immune system to identify
and eradicate malignant tumor cells while sparing the normal tissues. Furthermore, cancer …

The immune system plays a critical role in shaping all facets of cancer, from the early
initiation stage through to metastatic disease and resistance to therapy. Our understanding …